0000000001171060

AUTHOR

C De Nunzio

showing 3 related works from this author

Telehealth in Urology: A Systematic Review of the Literature. How Much Can Telemedicine Be Useful During and After the COVID-19 Pandemic?

2020

Context Coronavirus disease 2019 (COVID-19) pandemic has caused increased interest in the application of telehealth to provide care without exposing patients and physicians to the risk of contagion. The urological literature on the topic is sparse. Objective To perform a systematic review of the literature and evaluate all the available studies on urological applications of telehealth. Evidence acquisition After registration on PROSPERO, we searched PubMed and Scopus databases to collect any kind of studies evaluating any telehealth interventions in any urological conditions. The National Toxicology Program/Office of Health Assessment and Translation Risk of Bias Rating Tool for Human and A…

Coronavirus; COVID-19; E-health; Severe acute respiratory syndrome coronavirus 2; Telehealth; Telemedicinemedicine.medical_specialtyTelemedicineTelemedicine.UrologyUrinary systemCoronaviru030232 urology & nephrologyPsychological interventionUrinary incontinenceContext (language use)TelehealthArticleCOVID-19; Coronavirus; E-health; Severe acute respiratory syndrome coronavirus 2; Telehealth; Telemedicinelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawHealth caremedicineSevere acute respiratory syndrome coronavirus 2Intensive care medicineE-healthCOVID-19; Coronavirus; E-health; Severe acute respiratory syndrome coronavirus 2; Telehealth; Telemedicine.business.industryCOVID-19COVID-19 Coronavirus E-health Severe acute respiratory syndrome coronavirus 2 Telehealth Telemedicine.TelemedicineCoronavirusTelehealth030220 oncology & carcinogenesismedicine.symptombusinessCoronavirus COVID-19 E-health Severe acute respiratory syndrome coronavirus 2 Telehealth TelemedicineEuropean Urology
researchProduct

Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal V…

2014

Background: Approximately 10-20% of recurrences in patients treated with nephrectomy for renal cell carcinoma (RCC) develop beyond 5 yr after surgery (late recurrence). Objective: To determine features associated with late recurrence. Design, setting, and participants: A total of 5009 patients from a multicenter database comprising 13 107 RCC patients treated surgically had a minimum recurrence-free survival of 60 mo (median follow-up [FU]: 105 mo [range: 78-135]); at last FU, 4699 were disease free (median FU: 103 mo [range: 78-134]), and 310 patients (6.2%) experienced disease recurrence (median FU: 120 mo [range: 93-149]). Interventions: Patients underwent radical nephrectomy or nephron-…

MaleTime FactorsDatabases FactualLymphovascular invasionmedicine.medical_treatmentPredictive Value of Testcomputer.software_genreNephrectomyRisk modelDecision Support TechniqueRisk FactorsRetrospective StudieRenal cell carcinomaOdds Ratiolate recurrencenephrectomyMedicineMultivariate AnalysiFramingham Risk ScoreDatabaseKidney Neoplasmrenal carcinomaPrognostic parametersMiddle AgedNephrectomyKidney NeoplasmsTreatment OutcomeLymphatic MetastasisFemaleRadiologyNephron sparing surgeryPrognostic parameterHumanmedicine.medical_specialtyrenal cell carcinomarecurrenceLogistic ModelTime FactorUrologyReproducibility of ResultLate recurrencecancer-specific mortalityrisk scoreRisk AssessmentDisease-Free SurvivalDecision Support Techniquescancer-specific mortality; late recurrence; nephrectomy; prognostic parameters; renal cell carcinoma; risk scorePredictive Value of TestsLate RecurrenceHumansInternal validationCarcinoma Renal CellProportional Hazards ModelsRetrospective StudiesAgedNeoplasm StagingChi-Square Distributionbusiness.industryProportional hazards modelRisk Factorrenal cell carcinoma; recurrence; Cancer-specific mortality; Late recurrence; Nephrectomy; Prognostic parameters; Risk scoreCancer-specific mortalityReproducibility of ResultsLymphatic MetastasiRetrospective cohort studyOdds ratioprognostic parametersmedicine.diseaseConfidence intervalLogistic ModelsMultivariate AnalysisProportional Hazards ModelRisk scoreNeoplasm GradingNeoplasm Recurrence LocalbusinesscomputerCancer-specific mortality; Late recurrence; Nephrectomy; Prognostic parameters; Renal cell carcinoma; Risk score
researchProduct

The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study.

2022

Background Prostate cancer (PCa) is the second most common neoplasm in male patients. To date, there's no certain indication about the maximum waiting time (WT) acceptable for treatment beginning and the impact on oncological and functional outcomes has not been well established. Methods Data from the National Research Council PCa monitoring multicenter project in Italy (Pros-IT CNR) were prospectively collected and analyzed. WT was defined as the time from the bioptical diagnosis of PCa to the first treatment received. Patients were divided in two groups, using a time frame of 90 days. Quality of life was measured through the Italian version of the University of California Los Angeles-Pros…

Waiting timeMalemedicine.medical_specialtyWaiting ListsUrologyLymph node metastasisAndrogen deprivation therapySettore MED/06Prostate cancerPercutaneous Coronary Interventionprostate cancer radical prostatectomy screeningQuality of lifeSettore MED/36Internal medicinemedicineHumansWaiting lists; Prostatic neoplasms; Prostatectomy; Radiotherapy; Androgens; Humans; Male; Prostate; Quality of Life; Waiting Lists; Percutaneous Coronary Intervention; Prostatic NeoplasmsProstatectomySurgical approachRadiotherapybusiness.industryscreeningProstateCancerProstatic NeoplasmsWaiting timeprostate cancermedicine.diseaseradical prostatectomyNephrologyAndrogensQuality of LifeT-stagePositive Surgical Marginbusiness
researchProduct